Cerluten vs Thymalin

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Standard Khavinson-class dosing protocols use oral capsule formulations in 10–20 day cycles at 5–10mg per cycle (divided doses), followed by rest intervals — consistent with the gene-regulatory rather than continuous-receptor-occupancy mechanism proposed for this peptide class. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.

Thymic peptide bioregulator; restores thymic function and T-cell production; modulates cytokine balance; shown to extend lifespan in animal models

Thymalin is a polypeptide preparation and Khavinson-class bioregulator derived from thymic tissue, proposed to restore age-related immune dysfunction associated with thymic involution by supplying thymic hormonal signals that support T-lymphocyte differentiation, immune homeostasis, and immunological reserve in elderly subjects. As a thymic bioregulator, thymalin is proposed to modulate gene expression in aging lymphoid cells through peptide-chromatin interactions and to support thymopoiesis and T-cell maturation in subjects whose endogenous thymic output has declined with age-associated involution. Published observational research from the Khavinson laboratory documented that long-term supplementation with thymalin and related thymic and pineal peptides was associated with significantly reduced all-cause mortality in elderly cohorts over extended follow-up, and earlier work reported geroprotective effects of thymalin and epithalamin in Russian geriatric research populations. Thymalin is not FDA-approved; it is available as a clinical preparation in Russia, where it has regulatory approval for immune support in elderly patients, and its evidence base derives from Russian-origin observational and preclinical studies with limited independent replication by international standards. Thymalin benefits investigated in preclinical and clinical research include immune system restoration in aged subjects, improved T-lymphocyte counts and function, modulation of cytokine balance toward anti-inflammatory profiles, and partial reversal of age-associated thymic involution. Long-term studies in aged animal models have documented lifespan extension with thymalin administration, and observational research in elderly human cohorts using thymic peptide preparations has associated treatment with reduced all-cause mortality over multiyear follow-up periods — findings published in Russian medical literature. As a thymic bioregulator, thymalin is proposed to work by restoring the hormonal output of the aging thymus rather than by immunosuppression or direct cytokine administration, distinguishing it from synthetic immunomodulatory drugs. Research interest also includes thymalin for age-related infections susceptibility, autoimmune regulation, and overall immune resilience as part of longevity-focused bioregulator protocols.